Related Experiment Videos
Defining bacillus Calmette-Guerin refractory superficial bladder tumors
1Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
The Journal of Urology
|April 11, 2003
Summary
Identifying BCG-refractory bladder cancer requires a 6-month evaluation. Early response to bacillus Calmette-Guerin (BCG) treatment predicts long-term outcomes for high-risk superficial bladder tumors.
Area of Science:
- Urology
- Oncology
- Immunotherapy
Background:
- Superficial bladder cancer (SBC) poses a significant clinical challenge.
- Bacillus Calmette-Guerin (BCG) is a standard immunotherapy for high-risk SBC.
- Defining BCG-refractory disease is crucial for treatment stratification.
Purpose of the Study:
- To define bacillus Calmette-Guerin (BCG) refractory, high-risk, superficial bladder cancer.
- To evaluate the predictive value of early BCG response on tumor recurrence and progression.
Main Methods:
- Ninety-three patients with high-risk superficial bladder cancer received a 6-week induction course of BCG.
- Patient response was assessed at 3 and 6 months post-induction.
- Patients were randomized to receive maintenance BCG or no maintenance therapy.
Main Results:
- At 6 months, 80% of patients achieved a tumor-free status; 20% had persistent or recurrent disease.
- Maintenance BCG did not significantly improve recurrence rates compared to induction BCG alone.
- Response to BCG at 6 months was the strongest predictor of subsequent tumor recurrence and progression.
Conclusions:
- A minimum of 6 months of BCG treatment and follow-up is necessary to accurately identify BCG-refractory superficial bladder cancer.
- Early assessment of BCG efficacy is critical for managing high-risk bladder cancer patients.